Shanghai Sanyou Medical Co., Ltd. (688085.SS)
CNY 20.26
(-2.78%)
CNY 20.26
(-2.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 165.16 Million CNY | -33.08% |
| 2022 | 277.65 Million CNY | 8.12% |
| 2021 | 245.72 Million CNY | 68.38% |
| 2020 | 156.36 Million CNY | -2.26% |
| 2019 | 126.06 Million CNY | 58.19% |
| 2018 | 81.39 Million CNY | 261.78% |
| 2017 | 17.31 Million CNY | -12.27% |
| 2016 | 15.3 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 19.37 Million CNY | 1274.61% |
| 2024 Q1 | -5.57 Million CNY | -97.39% |
| 2024 Q3 | 11.55 Million CNY | -48.61% |
| 2023 Q2 | 45.47 Million CNY | 6.19% |
| 2023 Q3 | -7.32 Million CNY | -116.11% |
| 2023 Q4 | 47.54 Million CNY | 748.77% |
| 2023 Q1 | 42.82 Million CNY | -45.22% |
| 2023 FY | - CNY | -33.08% |
| 2022 Q4 | 78.17 Million CNY | 77.83% |
| 2022 Q3 | 43.96 Million CNY | -24.25% |
| 2022 Q2 | 58.03 Million CNY | 71.82% |
| 2022 Q1 | 33.77 Million CNY | -63.32% |
| 2022 FY | - CNY | 8.12% |
| 2021 Q1 | 28.24 Million CNY | -4.71% |
| 2021 FY | - CNY | 68.38% |
| 2021 Q4 | 92.08 Million CNY | 345.99% |
| 2021 Q3 | 20.64 Million CNY | -65.0% |
| 2021 Q2 | 58.98 Million CNY | 108.82% |
| 2020 FY | - CNY | -2.26% |
| 2020 Q4 | 29.64 Million CNY | -30.68% |
| 2020 Q3 | 42.76 Million CNY | 18.04% |
| 2020 Q2 | 36.22 Million CNY | 290.06% |
| 2020 Q1 | 9.28 Million CNY | 107.78% |
| 2019 Q1 | 24.49 Million CNY | 135.61% |
| 2019 FY | - CNY | 58.19% |
| 2019 Q4 | -119.31 Million CNY | -480.93% |
| 2019 Q3 | 31.32 Million CNY | -8.09% |
| 2019 Q2 | 34.08 Million CNY | 39.11% |
| 2018 FY | - CNY | 261.78% |
| 2018 Q4 | -68.8 Million CNY | 0.0% |
| 2017 FY | - CNY | -12.27% |
| 2016 FY | - CNY | 0.0% |